NIHR Alert: Rituximab helps cure almost all children with non-Hodgkin’s lymphoma

Expert commentary is provided on a randomised study that found the addition of rituximab to chemotherapy improved 3-year survival in children with mature B-cell non-Hodgkin’s lymphoma (94% v 82% chemotherapy alone), which was the basis of its approval for this indication.

NIHR Dissemination Centre